Definium Therapeutics, Inc.
DFTX
$17.64
-$0.45-2.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.06M | 14.69M | 11.09M | 8.80M | 10.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.58M | 45.67M | 40.90M | 32.16M | 32.46M |
| Operating Income | -47.58M | -45.67M | -40.90M | -32.16M | -32.46M |
| Income Before Tax | -50.44M | -67.27M | -42.74M | -23.35M | -34.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.44M | -67.27M | -42.74M | -23.35M | -34.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.44M | -67.27M | -42.74M | -23.35M | -34.74M |
| EBIT | -47.58M | -45.67M | -40.90M | -32.16M | -32.46M |
| EBITDA | -47.45M | -45.66M | -40.90M | -32.15M | -32.46M |
| EPS Basic | -0.50 | -0.78 | -0.50 | -0.27 | -0.41 |
| Normalized Basic EPS | -0.31 | -0.49 | -0.31 | -0.17 | -0.26 |
| EPS Diluted | -0.50 | -0.78 | -0.50 | -0.35 | -0.42 |
| Normalized Diluted EPS | -0.31 | -0.49 | -0.31 | -0.17 | -0.26 |
| Average Basic Shares Outstanding | 101.00M | 85.89M | 85.35M | 85.07M | 83.93M |
| Average Diluted Shares Outstanding | 101.00M | 85.89M | 85.35M | 87.09M | 83.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |